Neonatal alloimmune thrombocytopenia (NAIT) is a rare yet potentially life‐threatening condition caused by maternal sensitisation to fetal platelet antigens, most notably human platelet antigen 1a.

Neonatal alloimmune thrombocytopenia (NAIT) is a rare yet potentially life‐threatening condition caused by maternal sensitisation to fetal platelet antigens, most notably human platelet antigen ...

The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, Massachusetts ...

In neonates with sepsis, thrombocytopenia is a common hematologic abnormality that appears to be an early prognostic indicator of disease severity. It is known that severe fetal and neonatal ...

FNAIT, an alloimmune condition resulting in thrombocytopenia and hemorrhagic complications, often affects preterm infants already vulnerable to hypoxic-ischemic encephalopathy, bronchopulmonary ...

The study offers hope for the effective treatment of alloimmunisation. Another immunisation disorder in the fetus and newborn is fetal/neonatal alloimmune thrombocytopenia (FNAIT). The mother forms ...

A case of neonatal alloimmune thrombocytopenia (NAIT) secondary to human platelet antigen (HPA)-1a antibodies is reported. Additional multispecific HLA antibodies rendered volunteer donor platelet ...

U.S. FDA Fast Track designation in hemolytic disease of the fetus and newborn (HDFN) and warm autoimmune hemolytic anemia (wAIHA) in July 2019, gMG in December 2021, fetal and neonatal alloimmune ...

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published ...